Boston Scientific (BSX) Total Non-Current Liabilities (2009 - 2026)

Boston Scientific has disclosed Total Non-Current Liabilities across 18 years of filings, most recently posting $17.6 billion for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities rose 6.3% year-over-year to $17.6 billion; the TTM figure through Jun 2026 stood at $17.6 billion (up 6.3% YoY), while the FY2025 annual figure was $16.8 billion, up 8.21% from the prior year.
• Total Non-Current Liabilities came in at $17.6 billion for Q2 2026 at Boston Scientific, up from $15.8 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $17.6 billion in Q2 2026 to a low of $12.4 billion in Q3 2022.
• Average Total Non-Current Liabilities over 5 years is $14.6 billion, with a median of $14.6 billion recorded in 2024.
• Year-over-year, Total Non-Current Liabilities retreated 5.98% in 2023 and advanced 17.04% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $12.9 billion in 2022, then gained by 6.05% to $13.6 billion in 2023, then climbed by 13.81% to $15.5 billion in 2024, then increased by 8.21% to $16.8 billion in 2025, then climbed by 4.57% to $17.6 billion in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $17.6 billion in Q2 2026, $15.8 billion in Q1 2026, and $16.8 billion in Q4 2025.